CTOs on the Move

Bio-Solutions Corporation

www.biosolutionscorp.com

 
Bio-Solutions Corp, Owns and Markets Type2 Defense(TM), a glucose control dietary supplement powder formulated to support healthy glucose levels in addition to maintaining healthy blood pressure.   The company believes that there is a growing Diabetic target market place that lacks adequate healthy tools to maintain healthy blood glucose levels. Type2 Defense is a powder blend of natural ingredients that has been developed to maintain healthy blood glucose levels.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Spinal Dimensions

Spinal Dimensions is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quad Five Materials Bio

Quad Five Materials Bio is a Ryegate, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syan Biosciences

Syan Biosciences is a Halethorpe, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bio Focus DPI

Bio Focus DPI is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.